Skip to main content

Grafa News and Videos — Page 1412

Latest

Grafa

FDA grants priority review for Jazz Pharmaceuticals’ Ziihera in first-line gastric cancer

Jazz Pharmaceuticals (NASDAQ:JAZZ) announced on Monday that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review its supplemental Biologics License Application (sBLA) for Ziihera (zanidatamab-hrii).

Read more: FDA grants priority review for Jazz Pharmaceuticals’ Ziihera in first-line gastric cancer
Grafa

CorMedix’s Rezzayo meets primary endpoint in Phase III invasive fungal disease trial

CorMedix (NASDAQ:CRMD) announced positive topline results on Monday from the global Phase III ReSPECT trial evaluating REZZAYO (rezafungin) for the prevention of invasive fungal diseases in adult allogeneic hematopoietic stem cell transplant (HSCT) patients.

Read more: CorMedix’s Rezzayo meets primary endpoint in Phase III invasive fungal disease trial
Grafa

Intellia Therapeutics announces positive Phase 3 results for one-time HAE gene editing therapy

Intellia Therapeutics (NASDAQ:NTLA) today announced positive topline results from its pivotal Phase 3 HAELO clinical trial evaluating lonvoguran ziclumeran (lonvo-z), a one-time in vivo CRISPR-based gene editing therapy for patients with hereditary angioedema (HAE).

Read more: Intellia Therapeutics announces positive Phase 3 results for one-time HAE gene editing therapy

GET YOUR GRAFA EDGE NOW

We'll switch on a 30-day Edge trial as a welcome gift